2-((6-methylpyridin-2-yl)amino)ethanol | 1178357-09-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-((6-methylpyridin-2-yl)amino)ethanol
• 英文别名: 2-(6-methylpyridin-2-ylamino)ethanol；2-[(6-Methylpyridin-2-yl)amino]ethanol
• CAS: 1178357-09-9
• 化学式: C₈H₁₂N₂O
• 分子量: 152.196
• InChiKey: XAEYWDMKQJWCIZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  45.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-((6-methylpyridin-2-yl)amino)ethanol 、 2,6-双(氯甲基)-4-甲酚 在 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 以99.1%的产率得到2,2'-(2-hydroxy-5-methyl-1,3-phenylene)bis(methylene)bis(((6-methylpyridin-2-yl)methyl)azanediyl)diethanol
  参考文献：
  名称：

  Ligand modifications modulate the mechanism of binuclear phosphatase biomimetics

  摘要：

  Complexation of dimethyl-6,6'-(2-hydroxy-5-methyl-1,3-phenylene)bis(methylene)bis((2-hydroxyethyl) azanediyl)bis(methylene)dipicolinate (Me(2)H(3)L4) and 2,2'-(2-hydroxy-5-methyl-1,3-phenylene)bis(meth ylene)bis(((6-methylpyridin-2-yl)methy)azanediyl)diethanol (H(3)L5) with Zn(II) afforded the complexes [Zn-2(H(2)L4)(H2O)(2)](ClO4) and [Zn-2(H(2)L5)(CH3CO2)(H2O)](PF6)(2)center dot 2H(2)O, which were characterized by H-1 and C-13 NMR spectroscopy, mass spectrometry, microanalysis, and the former by X-ray crystallography. Functional studies of the zinc complexes with the substrate bis(2,4-dinitrophenyl)phosphate (BDNPP) showed the complexes to be competent catalysts with k(cat) = 3.52 +/- 0.03 x 10(-4) and 1.27 +/- 0.04 x 10(-3) s(-1) (K-m = 6.7 +/- 0.9; 13.8 +/- 1.5 mM), with catalytically relevant pK(a)s of 9.4 and 6.6, respectively. The pK(a) values are discussed with respect to the potential nucleophilic species and the effect of the donor environment. Crown Copyright (C) 2012 Published by Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.poly.2012.06.008
• 作为产物：
  描述：

  6-甲基-2-吡啶甲醛 、 C.I.酸性橙108 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以44.5%的产率得到2-((6-methylpyridin-2-yl)amino)ethanol
  参考文献：
  名称：

  Ligand modifications modulate the mechanism of binuclear phosphatase biomimetics

  摘要：

  Complexation of dimethyl-6,6'-(2-hydroxy-5-methyl-1,3-phenylene)bis(methylene)bis((2-hydroxyethyl) azanediyl)bis(methylene)dipicolinate (Me(2)H(3)L4) and 2,2'-(2-hydroxy-5-methyl-1,3-phenylene)bis(meth ylene)bis(((6-methylpyridin-2-yl)methy)azanediyl)diethanol (H(3)L5) with Zn(II) afforded the complexes [Zn-2(H(2)L4)(H2O)(2)](ClO4) and [Zn-2(H(2)L5)(CH3CO2)(H2O)](PF6)(2)center dot 2H(2)O, which were characterized by H-1 and C-13 NMR spectroscopy, mass spectrometry, microanalysis, and the former by X-ray crystallography. Functional studies of the zinc complexes with the substrate bis(2,4-dinitrophenyl)phosphate (BDNPP) showed the complexes to be competent catalysts with k(cat) = 3.52 +/- 0.03 x 10(-4) and 1.27 +/- 0.04 x 10(-3) s(-1) (K-m = 6.7 +/- 0.9; 13.8 +/- 1.5 mM), with catalytically relevant pK(a)s of 9.4 and 6.6, respectively. The pK(a) values are discussed with respect to the potential nucleophilic species and the effect of the donor environment. Crown Copyright (C) 2012 Published by Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.poly.2012.06.008

文献信息

• Amino heterocyclyl inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
  申请人：Cheng Hengmiao

  公开号：US20050148631A1

  公开（公告）日：2005-07-07

  The present invention relates to compounds with the formula (I), or a pharmaceutically acceptable salt thereof: The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) or formula (II) and methods of treating a condition that is mediated by the modulation of 11-β-hsd-1, the method comprising administering to a mammal an effective amount of a compound of formula (I) or formula (II).

  本发明涉及具有化学式(I)或其药学上可接受的盐的化合物：该发明还涉及包含化学式(I)或化学式(II)化合物的药物组合物，以及治疗通过调节11-β-hsd-1介导的疾病的方法，该方法包括向哺乳动物施用化学式(I)或化学式(II)化合物的有效量。
• Urea and urethane derivatives as integrin inhibitors
  申请人：——

  公开号：US20040063644A1

  公开（公告）日：2004-04-01

  Novel urea and urethane derivatives of general formula (I) in which R1, R2, R3, R5, R5′, X, Y, B, m, n and o are as defined in Patent claim 1, and physiologically acceptable salts or solvates thereof are integrin inhibitors and can be employed for combating thromboses, cardiac infarction, coronary heart disease, arteriosclerosis, inflammation, tumours. Osteoporosis, infections and restenosis after angioplasty or in pathological processes maintained or propagated by antiogenesis.

  通式（I）的新型脲和脲醚衍生物，其中R1、R2、R3、R5、R5'、X、Y、B、m、n和o如专利权要求书1中所定义，并且其生理上可接受的盐或溶剂化物是整合素抑制剂，可用于抗击血栓、心肌梗塞、冠心病、动脉硬化、炎症、肿瘤、骨质疏松症、感染和在抗血管生成维持或传播的病理过程中的再狭窄治疗。
• UREA AND URETHANE DERIVATIVES AS INTEGRIN INHIBITORS
  申请人：MERCK PATENT GmbH

  公开号：EP1343764A1

  公开（公告）日：2003-09-17
• US7135587B2
  申请人：——

  公开号：US7135587B2

  公开（公告）日：2006-11-14
• US7932270B2
  申请人：——

  公开号：US7932270B2

  公开（公告）日：2011-04-26